Allarity Therapeutics
$1.4200
67
+$0.01+0.71% Tuesday 20:00
+$0.03+2.11%Tuesday 23:30After hours
Statistics
Day High
1.4
Day Low
1.4
52W High
2.06
52W Low
0.769
Volume
942
Avg. Volume
-
Mkt Cap
22.59M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
12NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-8.4
-5.65
-2.9
-0.15
Expected EPS
-0.25
Actual EPS
N/A
Financials
-3,509.69%Profit Margin
Unprofitable320,000Revenue
-11.23MNet Income
Analyst Ratings
10.25Average Price Target
The highest estimate is 10.25.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow ALLR. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Merck
MRK
Mkt Cap366B
Pfizer
PFE
Mkt Cap159.36B
Novartis
NVS
Mkt Cap292.35B
Gilead Sciences
GILD
Mkt Cap180.64B
AMGEN
AMGN
Mkt Cap233.78B
Abbvie
ABBV
Mkt Cap451.46B
Astrazeneca
AZN
Mkt Cap252.33B
Roche
RHHBY
Mkt Cap334.28B
Lilly(Eli) &
LLY
Mkt Cap1.05T
About
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
Show more...
CEO
Thomas H. Jensen
Employees
8
Country
United States
ISIN
US0167445008
WKN
000A3D7BF
Listings
0 Comments
Share your thoughts
FAQ
What is Allarity Therapeutics stock price today?▼
The current price of ALLR is $1.42 USD — it has increased by +0.71% in the past 24 hours. Watch Allarity Therapeutics stock price performance more closely on the chart.
What is Allarity Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Allarity Therapeutics stocks are traded under the ticker ALLR.
Is Allarity Therapeutics stock price growing?▼
ALLR stock has risen by +5.97% compared to the previous week, the month change is a +17.36% rise, over the last year Allarity Therapeutics has showed a -11.25% decrease.
What is Allarity Therapeutics market cap?▼
Today Allarity Therapeutics has the market capitalization of 22.59M
When is the next Allarity Therapeutics earnings date?▼
Allarity Therapeutics is going to release the next earnings report on November 12, 2026.
What were Allarity Therapeutics earnings last quarter?▼
ALLR earnings for the last quarter are -0.21 USD per share, whereas the estimation was -0.25 USD resulting in a +16% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Allarity Therapeutics revenue for the last year?▼
Allarity Therapeutics revenue for the last year amounts to 320,000 USD.
What is Allarity Therapeutics net income for the last year?▼
ALLR net income for the last year is -11.23M USD.
How many employees does Allarity Therapeutics have?▼
As of September 02, 2026, the company has 8 employees.
In which sector is Allarity Therapeutics located?▼
Allarity Therapeutics operates in the Health & Wellness sector.
When did Allarity Therapeutics complete a stock split?▼
The last stock split for Allarity Therapeutics was on September 11, 2024 with a ratio of 1:30.
Where is Allarity Therapeutics headquartered?▼
Allarity Therapeutics is headquartered in BOSTON, United States.